Press Releases

SHANGHAI, March 7, 2026 — Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692.HK) today announced positive Phase 3 results for olatorepatide (HS-20094), an investigational once-weekly GLP-1/GIP receptor dual agonist, in adults with obesity or overweight.

The randomized, double-blind, placebo-controlled study enrolled 604 adults across 33 clinical sites and evaluated once-weekly olatorepatide versus placebo over 48 weeks. The study met its co-primary endpoints, demonstrating a statistically significant reduction in body weight from baseline at Week 48 and a statistically significantly greater proportion of participants achieving at least 5% weight loss at Week 48 with olatorepatide versus placebo. Participants treated with olatorepatide achieved up to 19.3% mean weight loss from baseline at Week 48. Responder analyses showed that up to 97.2% of participants achieved ≥5% weight loss at Week 48. These results demonstrate that a high proportion of participants achieved clinically meaningful weight-loss, with robust efficacy maintained through Week 48.

Olatorepatide demonstrated remarkably improved gastrointestinal tolerability in the study, with lower rates of gastrointestinal adverse events and treatment discontinuation relative to those reported in published Phase 3 dual incretin trials.

Detailed results from this Phase 3 study are planned to be presented at an upcoming international medical conference and submitted for publication in a peer-reviewed scientific journal.

"The clinical data for Olatorepatide is highly promising. The fact that body weight was still on a downward trajectory at 48 weeks indicates the compound's potential for deeper efficacy with long-term use," commented Principal Investigator, Department of Endocrinology, Peking University People's Hospital，Prof. Li-Nong Ji. "Furthermore, Olatorepatide demonstrated a gastrointestinal tolerability profile more favorable to that seen in other Phase 3 dual incretin studies. This improved tolerability is a significant advantage, as it may be more likely to facilitate sustained therapy and clearly differentiates olatorepatide within the dual incretin class."

“Gastrointestinal tolerability has long been a key barrier to improving patient adherence to treatment,” said Eliza Sun, Executive Director of the Board at Hansoh Pharma. “With its innovative dual-target design, olatorepatide delivers remarkable weight-loss efficacy while demonstrating improvements in gastrointestinal tolerability. The average incidence of nausea was below 10%, and the average incidence of vomiting was below 5%. We believe olatorepatide has the potential to become a more desirable treatment option for people living with overweight or obesity and this profile may help support long-term treatment adherence and provide a new treatment option for this population.”

About Olatorepatide (HS-20094)

Olatorepatide is an investigational once-weekly GLP-1/GIP dual receptor agonist designed to regulate metabolic pathways involved in appetite control, glucose metabolism and energy balance. By activating complementary incretin pathways, olatorepatide aims to deliver robust weight reduction while maintaining a favorable tolerability profile. Olatorepatide is currently being investigated in Phase III clinical studies for the treatment of obesity, overweight and type 2 diabetes. In June 2025, Hansoh Pharmaceutical entered into a licensing agreement with Regeneron Pharmaceuticals for olatorepatide. Under the agreement, Hansoh retains development and commercialization rights in Chinese mainland, Hong Kong and Macau, while Regeneron holds the rights outside these territories.

About Phase III Study Design (NCT06839664 / CTR20243973)

The Phase III randomized, double-blind, placebo-controlled, multicenter study in China evaluated the efficacy and safety of olatorepatide in adults with obesity or overweight. The study assessed four cohorts, 5mg, 10mg, 15mg and placebo treatment groups, utilizing a 1:1:1:1 randomization.

About Obesity

Obesity is a complex chronic disease driven by multiple factors. Currently, more than 650 million adults worldwide are affected, and the World Health Organization (WHO) has long recognized obesity as a major global public health epidemic requiring urgent action. According to data from 2025, the combined prevalence of overweight and obesity among adults in China has exceeded 50%^[1]. As a major risk factor for a range of chronic conditions, obesity significantly increases the risk of type 2 diabetes, cardiovascular diseases and certain cancers, posing a substantial challenge to public health.

References

[1] World Obesity Federation. World Obesity Atlas 2025. Overweight, obesity and non-communicable diseases. New global, regional and national estimates of the prevalence of overweight and obesity in adults from 2000 to 2030. Mar, 2025. //s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2025_rev1.pdf